[ad_1] Raising fresh capital is a familiar rhythm for early-stage biotech companies. For Poolbeg Pharma, the question is not simply whether it…

[ad_1] Are the green shoots starting to emerge for the junior market? Well, it certainly seems to be the case…

[ad_1] By IAN LYALL AT PROACTIVE INVESTORS FOR THISISMONEY.CO.UK Updated: 13:27, 10 March 2025 A 42 per cent profit. That’s…

[ad_1] Electric vehicles are constantly improving, but there’s no doubt these ever-evolving petrol and diesel alternatives still face scrutiny from…

[ad_1] For ambitious junior life sciences companies, often the ultimate goal is securing partnerships with well-funded industry players to propel…

[ad_1] Kromek Group left investors cheering this week as it unmasked a road to profitability via a deal with Siemens…

[ad_1] Britain is no longer the industrial powerhouse it once was, having ceded its dominance in manufacturing to the US,…

[ad_1] Switzerland will cap its population to ten million as part of an immigration crackdown under plans put forward by…

[ad_1] Why must everything be subscription-based these days?From entertainment, fitness, food and wine to beauty products and even underwear, it…

[ad_1] Allergy Therapeutics is writing a story of resilience and transformation. Putting behind it manufacturing setbacks, the company has redefined…